vimarsana.com

Latest Breaking News On - Mohamed al ibrahim - Page 1 : vimarsana.com

Immuron Clinical Trials Update

Immuron signs up second cohort for clinical trial assessing Travelan® in the prevention of travellers diarrhoea

Globally integrated biopharmaceutical company Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has initiated the second cohort of a clinical trial aimed at assessing the.

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced.

Immuron Announces Travelan® Clinical Study Cohort 2 commences - Immuron (NASDAQ:IMRN)

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second

Immuron enrols first patients in Travelan® clinical study

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has enrolled its first cohort of 30 participants into the Travelan® clinical trial to evaluate its efficacy to prevent.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.